Inactivated Influenza Vaccine in Infants 10-22 Weeks of Age
Influenza
About this trial
This is an interventional prevention trial for Influenza focused on measuring Influenza, Vaccine, Infants
Eligibility Criteria
Inclusion Criteria: Healthy infants, 10-22 weeks of age Up to date with routine immunizations (Hepatitis B [Hep B]; diphtheria, tetanus and pertussis [DTaP]; pneumococci [Prevnar]; polio [IPV]; Haemophilus influenzae type B [Hib]) Free of obvious health problems as established by medical history and clinical examination before entering into the study Parent/legal guardian willing and capable of signing written informed consent Parent/legal guardian expected to be available for entire study Parent/legal guardian can be reached by telephone. Exclusion Criteria: History of hypersensitivity to eggs or egg proteins Former premature infants (<37 weeks) History of wheezing or use of bronchodilator medication History of hospitalization (excluding birth) Significant underlying chronic illness (i.e. congenital heart defect, bronchopulmonary dysplasia, HIV) Immunodeficiency disease or use of immunosuppressive therapy by the participant Any other condition which in the clinical judgment of the investigator might interfere with vaccine evaluation Current enrollment and participation in a clinical trial for an investigational drug or vaccine Plans for participation in another clinical trial with an investigational drug or vaccine for the duration of this flu study.
Sites / Locations
- Cincinnati Children's Hospital Medical Center
- Vanderbilt University